Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T63966 | ||||
Target Name | Vascular endothelial growth factor receptor 1 (FLT-1) | ||||
Type of Target |
Successful |
||||
Drug Potency against Target | Sorafenib | Drug Info | Ki = 20~90 nM | [3] | |
Axitinib | Drug Info | IC50 = 1.2 nM | [8] | ||
Cediranib | Drug Info | IC50 = 2 nM | [6] | ||
CEP-11981 | Drug Info | IC50 = 12 nM | [2] | ||
KRN633 | Drug Info | IC50 = 1.16 nM | [4] | ||
Motesanib | Drug Info | IC50 = 2 nM | [5] | ||
SU-14813 | Drug Info | IC50 = 2 nM | [5] | ||
SU-11652 | Drug Info | IC50 = 50 nM | [1] | ||
Action against Disease Model | Sorafenib | Drug Info | Activity on H9c2 cellline is 10,160 nM | [7] | |
References | |||||
REF 1 | Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. | ||||
REF 2 | CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. 2003 Sep 15;63(18):5978-91. | ||||
REF 3 | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. | ||||
REF 4 | Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem. 2007;7(14):1379-93. | ||||
REF 5 | A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008 Jan;26(1):127-32. | ||||
REF 6 | Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opin Investig Drugs. 2008 Jul;17(7):1013-28. | ||||
REF 7 | Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008 Nov;106(1):153-61. | ||||
REF 8 | Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008 Nov 15;14(22):7272-83. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.